Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma

T. Ise; S. Nagata; R. J. Kreitman; W. H. Wilson; A. S. Wayne; M. Stetler-Stevenson; M. R. Bishop; D. A. Scheinberg; L. Rassenti; T. J. Kipps; R. A. Kyle; D. F. Jelinek; I. Pastan

doi:10.1038/sj.leu.2404445

Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma

T. Ise, S. Nagata, R. J. Kreitman, W. H. Wilson, A. S. Wayne, M. Stetler-Stevenson, M. R. Bishop, D. A. Scheinberg, L. Rassenti, T. J. Kipps, R. A. Kyle, D. F. Jelinek, I. Pastan

Immunology

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

CD307 is a differentiation antigen expressed in B-lineage cells. One soluble and two membrane-bound forms have been predicted and an enzyme-linked immunosorbent assay (ELISA) for soluble CD307 established. Our goal was to determine if CD307 is expressed on the surface of cells from patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other B-cell malignancies and if soluble CD307 levels are elevated in the blood of patients with these B-cell malignancies. Cells and blood were collected from patients. Expression of CD307 was measured by flow cytometry and blood levels of soluble CD307 by ELISA. High soluble CD307 levels were detected in 21/43 (49%) of patients with MM, 36/46 (78%) with CLL and 9/24 (38%) with MCL. Soluble CD307 levels correlated with plasma cell percentages in bone marrow aspirates in MM and total white blood cells in CLL. CD307 on the cell membrane was detected by flow cytometry in 8/8 MM, 23/29 CLL and 4/ 5 MCL samples. Because CD307 is present on malignant cells from patients with MM, CLL and MCL, CD307 may be a useful therapeutic target for the treatment of these diseases.

Original language	English (US)
Pages (from-to)	169-174
Number of pages	6
Journal	Leukemia
Volume	21
Issue number	1
DOIs	https://doi.org/10.1038/sj.leu.2404445
State	Published - Jan 2007

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/sj.leu.2404445

Cite this

Ise, T., Nagata, S., Kreitman, R. J., Wilson, W. H., Wayne, A. S., Stetler-Stevenson, M., Bishop, M. R., Scheinberg, D. A., Rassenti, L., Kipps, T. J., Kyle, R. A., Jelinek, D. F., & Pastan, I. (2007). Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia, 21(1), 169-174. https://doi.org/10.1038/sj.leu.2404445

Ise, T, Nagata, S, Kreitman, RJ, Wilson, WH, Wayne, AS, Stetler-Stevenson, M, Bishop, MR, Scheinberg, DA, Rassenti, L, Kipps, TJ, Kyle, RA, Jelinek, DF & Pastan, I 2007, 'Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma', Leukemia, vol. 21, no. 1, pp. 169-174. https://doi.org/10.1038/sj.leu.2404445

@article{4b70349c9f554d06abd01e53f73ca8ae,

title = "Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma",

abstract = "CD307 is a differentiation antigen expressed in B-lineage cells. One soluble and two membrane-bound forms have been predicted and an enzyme-linked immunosorbent assay (ELISA) for soluble CD307 established. Our goal was to determine if CD307 is expressed on the surface of cells from patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other B-cell malignancies and if soluble CD307 levels are elevated in the blood of patients with these B-cell malignancies. Cells and blood were collected from patients. Expression of CD307 was measured by flow cytometry and blood levels of soluble CD307 by ELISA. High soluble CD307 levels were detected in 21/43 (49%) of patients with MM, 36/46 (78%) with CLL and 9/24 (38%) with MCL. Soluble CD307 levels correlated with plasma cell percentages in bone marrow aspirates in MM and total white blood cells in CLL. CD307 on the cell membrane was detected by flow cytometry in 8/8 MM, 23/29 CLL and 4/ 5 MCL samples. Because CD307 is present on malignant cells from patients with MM, CLL and MCL, CD307 may be a useful therapeutic target for the treatment of these diseases.",

author = "T. Ise and S. Nagata and Kreitman, {R. J.} and Wilson, {W. H.} and Wayne, {A. S.} and M. Stetler-Stevenson and Bishop, {M. R.} and Scheinberg, {D. A.} and L. Rassenti and Kipps, {T. J.} and Kyle, {R. A.} and Jelinek, {D. F.} and I. Pastan",

note = "Funding Information: This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.",

year = "2007",

month = jan,

doi = "10.1038/sj.leu.2404445",

language = "English (US)",

volume = "21",

pages = "169--174",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma

AU - Ise, T.

AU - Nagata, S.

AU - Kreitman, R. J.

AU - Wilson, W. H.

AU - Wayne, A. S.

AU - Stetler-Stevenson, M.

AU - Bishop, M. R.

AU - Scheinberg, D. A.

AU - Rassenti, L.

AU - Kipps, T. J.

AU - Kyle, R. A.

AU - Jelinek, D. F.

AU - Pastan, I.

N1 - Funding Information: This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

PY - 2007/1

Y1 - 2007/1

N2 - CD307 is a differentiation antigen expressed in B-lineage cells. One soluble and two membrane-bound forms have been predicted and an enzyme-linked immunosorbent assay (ELISA) for soluble CD307 established. Our goal was to determine if CD307 is expressed on the surface of cells from patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other B-cell malignancies and if soluble CD307 levels are elevated in the blood of patients with these B-cell malignancies. Cells and blood were collected from patients. Expression of CD307 was measured by flow cytometry and blood levels of soluble CD307 by ELISA. High soluble CD307 levels were detected in 21/43 (49%) of patients with MM, 36/46 (78%) with CLL and 9/24 (38%) with MCL. Soluble CD307 levels correlated with plasma cell percentages in bone marrow aspirates in MM and total white blood cells in CLL. CD307 on the cell membrane was detected by flow cytometry in 8/8 MM, 23/29 CLL and 4/ 5 MCL samples. Because CD307 is present on malignant cells from patients with MM, CLL and MCL, CD307 may be a useful therapeutic target for the treatment of these diseases.

AB - CD307 is a differentiation antigen expressed in B-lineage cells. One soluble and two membrane-bound forms have been predicted and an enzyme-linked immunosorbent assay (ELISA) for soluble CD307 established. Our goal was to determine if CD307 is expressed on the surface of cells from patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other B-cell malignancies and if soluble CD307 levels are elevated in the blood of patients with these B-cell malignancies. Cells and blood were collected from patients. Expression of CD307 was measured by flow cytometry and blood levels of soluble CD307 by ELISA. High soluble CD307 levels were detected in 21/43 (49%) of patients with MM, 36/46 (78%) with CLL and 9/24 (38%) with MCL. Soluble CD307 levels correlated with plasma cell percentages in bone marrow aspirates in MM and total white blood cells in CLL. CD307 on the cell membrane was detected by flow cytometry in 8/8 MM, 23/29 CLL and 4/ 5 MCL samples. Because CD307 is present on malignant cells from patients with MM, CLL and MCL, CD307 may be a useful therapeutic target for the treatment of these diseases.

UR - http://www.scopus.com/inward/record.url?scp=33845531300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845531300&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404445

DO - 10.1038/sj.leu.2404445

M3 - Article

C2 - 17051241

AN - SCOPUS:33845531300

SN - 0887-6924

VL - 21

SP - 169

EP - 174

JO - Leukemia

JF - Leukemia

IS - 1

ER -

Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this